<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148759</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00002448</org_study_id>
    <secondary_id>UPN 04092824</secondary_id>
    <secondary_id>GCRC0605G</secondary_id>
    <nct_id>NCT00148759</nct_id>
  </id_info>
  <brief_title>Kaletra Sex/Gender Pharmacokinetics (PK) Study</brief_title>
  <acronym>LPVGenderPK</acronym>
  <official_title>A Switch From Twice Daily to Once Daily Lopinavir/Ritonavir: A 24-hour Pharmacokinetic Profile to Evaluate Sex Differences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The levels of lopinavir achieved in the blood following oral ingestion of standard doses of
      Kaletra (lopinavir/ritonavir) in HIV-infected men was compared with those achieved in
      HIV-infected women receiving the same dose of the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The association between patient sex and the tolerability of antiretroviral drugs (ARVs) is
      increasingly being recognized. Several lines of evidence suggest that women are more likely
      than men to develop side effects to ARVs. On the other hand, it has been generally accepted
      that the efficacies of the ARVs are similar in both sexes. However, recent studies suggest
      that this may not always be the case. In addition to these observed sex-related differences
      in the effects of ARVs, there is growing evidence that the pharmacokinetic profile of some of
      these drugs may be different among male and female HIV infected patients.

      The fact that female sex is a risk factor for enhanced antiretroviral effects (including
      toxicities) has an important implication, particularly from a global health perspective as
      women now represent the fastest growing segment of the HIV/AIDS epidemic. Therefore, an
      understanding of the magnitude, clinical significance, and the mechanisms underlying this
      phenomenon deserves further study. Knowledge acquired from such studies will likely
      contribute to improved survival among female HIV-infected patients, through optimization of
      antiretroviral therapeutic regimens in manners that minimize serious adverse effects and
      improve adherence.

      Similarly, the influence of race on the pharmacological effects of ARVs deserves further
      investigation. Although, there is no reason to believe based on available evidence that
      racial differences exist in the pharmacological effects of ARVs, the need however exists to
      explore the influence of race on ARVs pharmacokinetics and treatment outcomes. This is so
      because data on race related differences on ARV effects is limited, and in addition, people
      of ethnic minority have been disproportionately under represented in clinical trials
      involving these drugs in spite of the fact that they bear a larger burden of the HIV
      epidemic.

      Our study will examine the influence of race and sex on the 24-hr pharmacokinetics of
      lopinavir/ritonavir (an antiretroviral agent commonly used in naïve patients) following a
      switch from LPV/r 400/100 mg twice daily to 800/200 mg once daily dosing. Tolerability
      (measured by toxicity grade of diarrhea) and change in quality of life following switch from
      twice daily to once daily dosing will also be assessed using appropriate validated
      measurement tools.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hr LPV AUC</measure>
    <time_frame>24 hours</time_frame>
    <description>Steady state(2 weeks after therapy change)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hr LPV Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>LPV Cmax at Steady State</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>adult male subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LPV/r 800/200 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult female subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LPV/r 800/200 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LPV/r</intervention_name>
    <description>LPV/r 800/200 mg once daily</description>
    <arm_group_label>adult male subjects</arm_group_label>
    <arm_group_label>Adult female subjects</arm_group_label>
    <other_name>Daily LPV/r</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater or equal to 18 years

          -  Diagnosis of HIV infection as previously established by HIV Enzyme-Linked
             Immunosorbent Assay (ELISA) test and confirmed by Western blot analysis.

          -  Must have been taking LPV/r as part of an antiretroviral regimen at a dose of 400/100
             mg orally twice per day for at least 3 months.

          -  Recent (within last 90 days) HIV-RNA copies must be less than 400 copies/ml

        Exclusion Criteria:

          -  Hepatic abnormality: alanine-aminotransferase (ALT), aspartate-aminotransferase (AST)
             or total bilirubin (TBR) ≥ 3 x upper limit of normal

          -  Renal insufficiency: serum creatinine ≥ 2 mg/dl

          -  Co-infection with hepatitis B and/or C viruses

          -  Pregnant or breastfeeding

          -  Use of concurrent medications known to affect lopinavir or ritonavir concentrations
             significantly.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igho Ofotokun, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Infectious Diseases Program</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ofotokun I, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol. 2007 Aug;47(8):970-7. Epub 2007 Jul 5.</citation>
    <PMID>17615254</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <results_first_submitted>November 24, 2009</results_first_submitted>
  <results_first_submitted_qc>August 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2013</results_first_posted>
  <last_update_submitted>November 8, 2013</last_update_submitted>
  <last_update_submitted_qc>November 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Ighovwerha Ofotokun</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sex differences</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Lopinavir/ritonavir</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>HIV-infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Grady Infectious Diseases Clinic in Atlanta, Georgia between June 2005 and January 2007. All subjects provided written informed consent before undergoing any study procedures.</recruitment_details>
      <pre_assignment_details>Of the 23 subjects enrolled, 20 completed the study including the PK sampling. Three subjects (2 males and 1 female) dropped out. Two subjects were unavailable for the 24-hour PK sampling because of changes in their work schedules, and the third subject was lost to follow-up after the initial study visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Male Arm</title>
          <description>Male subjects</description>
        </group>
        <group group_id="P2">
          <title>Female Arm</title>
          <description>Female subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>24-hr PK Sampling</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Male subjects</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Female subjects</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="16"/>
                    <measurement group_id="B2" value="39" spread="18"/>
                    <measurement group_id="B3" value="38" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>24-hr LPV Cmax</title>
        <description>LPV Cmax at Steady State</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Male subjects</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Female subjects</description>
          </group>
        </group_list>
        <measure>
          <title>24-hr LPV Cmax</title>
          <description>LPV Cmax at Steady State</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12417" lower_limit="11622" upper_limit="13699"/>
                    <measurement group_id="O2" value="12271" lower_limit="7219" upper_limit="14113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>24-hr LPV AUC</title>
        <description>Steady state(2 weeks after therapy change)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Male subjects</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Female subjects</description>
          </group>
        </group_list>
        <measure>
          <title>24-hr LPV AUC</title>
          <description>Steady state(2 weeks after therapy change)</description>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142,160" lower_limit="136300" upper_limit="191390"/>
                    <measurement group_id="O2" value="152140" lower_limit="110840" upper_limit="214180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Male subjects</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Female subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ighovwerha Ofotokun, MD, MSc</name_or_title>
      <organization>Emory University</organization>
      <phone>404-616-0659</phone>
      <email>iofotok@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

